These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30673076)

  • 1. Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers.
    Pinard J; Femia AN; Roman M; Alsarheed A; Joyce C; Lin J; Vleugels RA
    JAMA Dermatol; 2019 Apr; 155(4):494-496. PubMed ID: 30673076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyopathic dermatomyositis with plantar keratoderma responding to methotrexate therapy.
    Morrell TJ; Mortensen WS; Langley S
    Cutis; 2017 Aug; 100(2):E20-E24. PubMed ID: 28961302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis.
    Kasteler JS; Callen JP
    J Am Acad Dermatol; 1997 Jan; 36(1):67-71. PubMed ID: 8996263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.
    Mittal L; Werth VP
    J Am Acad Dermatol; 2017 Aug; 77(2):374-377. PubMed ID: 28711090
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognosis of adult-onset clinically amyopathic dermatomyositis treated with only topical therapy.
    Matsuo Y; Mihara S; Tanaka A; Kawai M; Hide M
    J Dermatol; 2017 Jul; 44(7):e178-e179. PubMed ID: 28266052
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.
    Wolstencroft PW; Chung L; Li S; Casciola-Rosen L; Fiorentino DF
    JAMA Dermatol; 2018 Jan; 154(1):44-51. PubMed ID: 29114741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of clinical characteristics, work-up, treatment, and association to malignancy in dermatomyositis between two tertiary skin centers in the USA and Singapore.
    Yosipovitch G; Tan A; LoSicco K; Manabat CG; Kannagra A; Carroll C; Chan YH; Ng P; Jorizzo J
    Int J Dermatol; 2013 Jul; 52(7):813-9. PubMed ID: 22835263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linear amyopathic dermatomyositis with calcinosis cutis responsive to topical sodium thiosulfate.
    Topham C; Haynes D; Frigerio A; Hull C
    Pediatr Dermatol; 2019 Jul; 36(4):e102-e103. PubMed ID: 31134636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort.
    Galimberti F; Li Y; Fernandez AP
    Br J Dermatol; 2016 Jan; 174(1):158-64. PubMed ID: 26490490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyopathic dermatomyositis--an uncommon presentation of dermatomyositis.
    Arnson Y; Dovrish Z; Hadari R; Amital H
    Isr Med Assoc J; 2007 Jun; 9(6):492-3. PubMed ID: 17642406
    [No Abstract]   [Full Text] [Related]  

  • 11. Leflunomide as adjuvant treatment of dermatomyositis.
    Boswell JS; Costner MI
    J Am Acad Dermatol; 2008 Mar; 58(3):403-6. PubMed ID: 18194823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignancy-associated dermatomyositis: Retrospective case-control study from a single tertiary care center.
    Kooistra L; Ricotti C; Galimberti F; Gota C; Fernandez AP
    J Am Acad Dermatol; 2018 Jul; 79(1):152-155. PubMed ID: 29307640
    [No Abstract]   [Full Text] [Related]  

  • 13. Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease.
    Patel B; Khan N; Werth VP
    J Am Acad Dermatol; 2018 Jul; 79(1):77-83.e1. PubMed ID: 29291954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions.
    Hornung T; Ko A; Tüting T; Bieber T; Wenzel J
    Clin Exp Dermatol; 2012 Mar; 37(2):139-42. PubMed ID: 21981743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Rare Case of Amyopathic Juvenile Dermatomyositis Associated With Psoriasis Successfully Treated With Ustekinumab.
    Montoya CL; Gonzalez ML; Ospina FE; Tobón GJ
    J Clin Rheumatol; 2017 Mar; 23(2):129-130. PubMed ID: 28099216
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical improvement of a patient with both amyopathic dermatomyositis and psoriasis following treatment with cyclosporine.
    Inkeles MS; No D; Wu JJ
    Dermatol Online J; 2017 Aug; 23(8):. PubMed ID: 29469754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review.
    Callander J; Robson Y; Ingram J; Piguet V
    Br J Dermatol; 2018 Dec; 179(6):1248-1255. PubMed ID: 27167896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
    Ang GC; Werth VP
    Arch Dermatol; 2005 Jul; 141(7):855-9. PubMed ID: 16027300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous amyloidosis associated with amyopathic dermatomyositis.
    Taniguchi Y; Horino T; Terada Y
    J Rheumatol; 2009 May; 36(5):1088-9. PubMed ID: 19435977
    [No Abstract]   [Full Text] [Related]  

  • 20. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2012 Aug; 22(4):625-9. PubMed ID: 22124544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.